CRISPR: Editing Life

Few developments in the history of molecular biology have arrived with the disruptive force of CRISPR-Cas9. What began as a peculiar observation in the immune memory of bacteria has, in roughly a decade, been engineered into a molecular tool capable of rewriting the genomes of virtually any living organism with speed, precision, and a simplicity that earlier gene-editing platforms could not approach. As of 2026, CRISPR has moved from the research bench into the clinic, produced the first approved genomic medicines in human history, and spawned an expanding family of successor technologies, each designed to extend the reach and exactitude of deliberate genome modification. Understanding what CRISPR is, how it functions at the molecular level, what its current therapeutic landscape looks like, and where its unresolved challenges lie is no longer a matter of frontier literacy alone. It is a prerequisite for engaging with the biology and medicine of our time.

From Bacterial Immune Memory to Universal Editing Platform

The origin of the CRISPR system lies not in the ambitions of biotechnology but in the survival strategies of prokaryotes. Clustered Regularly Interspaced Short Palindromic Repeats were first noted in the genome of Escherichia coli in 1987, though their adaptive immune function would not be deciphered for nearly two more decades. Bacteria and archaea use CRISPR loci as a molecular memory bank, integrating short fragments of viral DNA, called spacers, between palindromic repeat sequences after surviving bacteriophage infection. When the same phage invades again, the spacer sequences are transcribed into CRISPR RNAs (crRNAs) that guide Cas nucleases to the viral genome, which is then cleaved and destroyed. This constitutes an elegant example of adaptive, heritable immunity at the prokaryotic level.

The critical conceptual leap came when researchers recognised that this RNA-guided recognition mechanism could be reprogrammed. A landmark 2012 study by Jennifer Doudna and Emmanuelle Charpentier demonstrated that a simplified, two-component system combining a Cas9 nuclease with a single guide RNA (sgRNA), an engineered fusion of crRNA and tracrRNA, could be directed to cut any double-stranded DNA sequence adjacent to a short protospacer adjacent motif (PAM) sequence. For the most widely used Streptococcus pyogenes Cas9 (SpCas9), this PAM is the three-nucleotide sequence 5′-NGG-3′. By altering just the 20-nucleotide spacer sequence within the sgRNA, researchers could redirect the same Cas9 protein to any genomic locus of interest, making the system trivially reprogrammable compared to the protein-engineering demands of zinc-finger nucleases or TALENs. Doudna and Charpentier were awarded the Nobel Prize in Chemistry in 2020 for this work.

Once introduced into a cell, the Cas9-sgRNA ribonucleoprotein complex scans DNA through a mechanism involving transient R-loop formation and strand invasion. Recognition of a complementary target sequence followed by a cognate PAM triggers conformational changes in Cas9 that activate two nuclease domains, HNH and RuvC, each responsible for cleaving one strand of the double helix. The resulting double-strand break (DSB) is then processed by the cell’s own DNA repair machinery. Non-homologous end joining (NHEJ), the predominant pathway in most cell types, rejoins the break rapidly but imprecisely, generating small insertions or deletions (indels) that frequently disrupt the open reading frame of a gene and abolish its function. When a repair template carrying the desired sequence is co-delivered, the less frequent homology-directed repair (HDR) pathway can incorporate precise substitutions, insertions, or corrections at the cut site. The relative efficiency of these two pathways varies considerably by cell cycle stage, cell type, and the size of the intended edit, factors that remain active areas of engineering optimisation.

Molecular Architecture: Cas9 and Beyond

The Cas9 Enzyme and Its Variants

The original SpCas9, at approximately 1,368 amino acids and roughly 160 kilodaltons (kDa), remains the workhorse of the field, but its size imposes delivery constraints, and its absolute dependence on the NGG PAM limits the density of editable sites across any given genome. Structural and directed evolution studies have generated a portfolio of engineered variants that address these limitations. SpCas9-HF1, eSpCas9, and evoCas9 all carry mutations in residues that make non-specific contacts with the DNA phosphate backbone, reducing tolerance for mismatches and substantially decreasing off-target cleavage while largely preserving on-target efficiency. PAM-relaxed variants such as SpRY, engineered through phage-assisted continuous evolution, can recognise near-arbitrary PAM sequences, dramatically expanding the targetable space within mammalian genomes.

Smaller orthologues discovered in other bacterial species have addressed the packaging problem. Staphylococcus aureus Cas9 (SaCas9), at approximately 1,053 amino acids, fits within a single adeno-associated virus (AAV) vector together with its guide RNA, a capability that SpCas9 lacks. CjCas9 from Campylobacter jejuni is even smaller. The class 2 type V effectors, notably Cas12a (formerly Cpf1), introduce staggered rather than blunt DSBs, process their own pre-crRNA arrays without a tracrRNA, and are active at AT-rich PAM sequences (5′-TTTV-3′ for Acidaminococcus sp. Cas12a), making them preferred tools in organisms with AT-rich genomes or for multiplexed editing strategies that exploit crRNA array processing. The type VI system, represented by Cas13 family members, cleaves single-stranded RNA rather than DNA, opening a distinct application space in transcriptome modulation and nucleic acid diagnostics.

The CRISPR Classification Framework

The broader CRISPR-Cas system is classified into two classes based on the complexity of the effector module. Class 1 systems employ multi-subunit complexes encoded by multiple Cas genes and, while potent in bacteria, have proved difficult to repurpose for mammalian genome editing. Class 2 systems, which include types II, V, and VI, utilise a single effector nuclease and have therefore been the focus of nearly all biotechnology and therapeutic development. Within class 2, type II systems use Cas9, type V systems include Cas12 variants, and type VI systems encode Cas13. This classification is not merely taxonomic. It reflects fundamental differences in PAM requirements, cleavage patterns, crRNA processing, and substrate specificity that determine which system is most appropriate for a given application.

Next-Generation Editing: Base Editors and Prime Editors

Base Editing: Precision Chemistry Without Double-Strand Breaks

A profound limitation of standard CRISPR-Cas9 editing is its dependence on DSBs, which are intrinsically mutagenic events. NHEJ-generated indels are useful for gene disruption but inappropriate for correcting pathogenic point mutations, which account for a large proportion of monogenic diseases. Base editing, developed principally by David Liu’s laboratory at the Broad Institute, addresses this by coupling a catalytically impaired Cas9 (a “nickase” or fully dead dCas9) to a deaminase enzyme that chemically converts one DNA base into another within a defined editing window near the PAM-proximal region of the target.

Cytosine base editors (CBEs) fuse a cytidine deaminase to nCas9 or dCas9 and convert cytosine to uracil within the editing window, which is then read as thymine after replication, yielding a net C-to-T (or G-to-A on the complementary strand) transition. Adenine base editors (ABEs), which required the directed evolution of a non-naturally occurring tRNA adenosine deaminase, convert adenine to inosine, which is then read as guanine, yielding A-to-G (or T-to-C) transitions. More recently, glycosylase base editors (GBEs) and dual base editors (DBEs) capable of C-to-G transversions or simultaneous C-to-T and A-to-G conversions have extended the reachable sequence space. Critically, none of these systems requires a donor DNA template, and the absence of a DSB dramatically reduces the frequency of large genomic rearrangements, translocations, and complex indels. Editing windows are typically 4 to 8 nucleotides in width, measured from the PAM-distal end, and engineered variants such as YE1-BE4, SECURE-BE3, and ABE8e-V106W have been developed specifically to narrow this window and reduce unintended RNA off-target deamination activity.

Prime Editing: A Search-and-Replace Mechanism

Prime editing, introduced in 2019 and undergoing rapid optimisation since, provides an even broader editing capability. A prime editor consists of a Cas9 nickase fused to an engineered reverse transcriptase, directed by a prime editing guide RNA (pegRNA) that contains both the spacer sequence targeting the locus and an extension encoding a primer binding site (PBS) and a reverse transcription (RT) template carrying the desired edit. After the nickase nicks the non-template strand, the 3′ flap generated by strand displacement hybridises to the PBS within the pegRNA extension. The fused reverse transcriptase then copies the RT template directly into the nicked strand, introducing the desired sequence, which may include substitutions, small insertions, or small deletions of any base composition. Unlike base editors, prime editors can in principle install all twelve types of single-base conversions and indels up to dozens of nucleotides in length without requiring a DSB or an exogenous DNA donor.

The primary engineering challenge for prime editing has been efficiency, which in early iterations was substantially lower than CBE or ABE in most cell types. A key insight came from the discovery that the cellular DNA mismatch repair (MMR) pathway actively suppresses prime editing outcomes and generates indel byproducts. Transient co-expression of a dominant negative MMR protein (MLH1dn) substantially boosted editing efficiency, a strategy incorporated into the PE4 and PE5 architectures. Subsequent versions, including PEmax, further optimised the codon usage and nuclear localisation of the editor and improved the pegRNA architecture through engineered 3′ extensions that protect against degradation. As of 2025, multiple research groups and the biotechnology company Prime Medicine have initiated or are planning clinical trials utilising prime editing for conditions including alpha-1 antitrypsin deficiency, with broader disease targets anticipated in 2026.

CRISPR in Medicine: From Proof of Concept to Approved Therapies

Casgevy and the First Clinical Milestone

The translation of CRISPR into approved human medicine was achieved with remarkable speed. In December 2023, the United States Food and Drug Administration (FDA) approved Casgevy (exagamglogene autotemcel, or exa-cel), developed jointly by CRISPR Therapeutics and Vertex Pharmaceuticals, for the treatment of sickle cell disease (SCD) in patients aged 12 years and older with recurrent vaso-occlusive crises. This approval represented the first regulatory authorisation of a CRISPR-based therapeutic anywhere in the world and followed earlier approvals in the United Kingdom for both SCD and transfusion-dependent beta-thalassemia (TDT). As of early 2026, Casgevy has received regulatory approval in the United States, United Kingdom, European Union, Switzerland, Canada, Bahrain, Saudi Arabia, and the United Arab Emirates, with 50 active treatment sites opened across North America, the EU, and the Middle East.

The mechanism of Casgevy is grounded in the reactivation of fetal hemoglobin (HbF). In SCD, a single A-to-T transversion in codon 6 of the beta-globin gene (HBB) causes the substitution of glutamic acid by valine, producing sickle hemoglobin (HbS) that polymerizes under deoxygenated conditions and deforms erythrocytes into the characteristic rigid sickle morphology. Fetal hemoglobin, produced from gamma-globin genes (HBG1/HBG2), does not contain the beta-chain and is unaffected by this mutation. In healthy adults, HbF expression is repressed after birth through the action of BCL11A, a transcription factor that silences the gamma-globin genes at the erythroid-specific enhancer of the BCL11A locus. The therapeutic approach employed in Casgevy involves the ex vivo CRISPR-Cas9 editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs), specifically disrupting the erythroid-specific enhancer within BCL11A. This reduces BCL11A expression selectively in erythroid lineage cells, relieving repression of gamma-globin and causing a substantial and sustained elevation of HbF in circulating red blood cells. Clinical trial data demonstrated that elevated HbF prevents HbS polymerization and sickling, abolishing vaso-occlusive crises in the large majority of treated patients and eliminating transfusion dependence in those with TDT.

The Expanding Clinical Landscape

Beyond SCD and TDT, the clinical trial landscape for CRISPR-based therapies has expanded rapidly. As of December 2025, 136 CRISPR clinical trials are ongoing globally, including 36 trials employing in vivo delivery of CRISPR components, a category that has grown substantially as delivery technologies have matured. The disease targets represented span haematology, immunology, oncology, cardiology, and several rare monogenic disorders.

In oncology, allogeneic CRISPR-edited CAR-T cell therapies are being evaluated. Allogene Therapeutics shared early Phase I data in June 2025 from a trial of allogeneic CRISPR-edited CD70-targeting CAR-T cells in metastatic renal cell carcinoma. In cardiovascular medicine, clinical trials targeting PCSK9, a serine protease that regulates LDL receptor recycling, are testing the durable reduction of circulating LDL cholesterol through a single in vivo editing event. Additional trials by Intellia Therapeutics have used lipid nanoparticle (LNP)-based delivery to target the liver for conditions including transthyretin amyloidosis. In rare immunodeficiencies, Beam Therapeutics has initiated a trial of a base editing treatment for severe SCD under the BEACON programme, while separate phase I/II trials are underway for X-linked severe combined immunodeficiency (SCID-X1) using base editing of the IL2RG gene in immune stem cells, with planned enrollment of twelve participants aged three and older beginning in 2025. Two trials for chronic granulomatous disease (CGD), targeting different causative mutations in NADPH oxidase subunit genes, are also active.

A particularly striking development arrived in 2025, when a personalised, bespoke in vivo CRISPR therapy was designed, manufactured, and administered to an individual infant patient in just six months, a feat that illustrated both the increasing speed of CRISPR-based therapeutic development and the potential of the platform for truly individualised medicine. This effort, involving researchers affiliated with the Innovative Genomics Institute, represents an early but significant proof of principle for on-demand genomic intervention.

Delivery: The Persistent Bottleneck

Ex Vivo and In Vivo Strategies

The efficacy of any CRISPR therapy depends not only on the editing chemistry but on the mechanism by which the editing components reach the target cell population. Two broad strategic frameworks exist. Ex vivo editing, as used in Casgevy, involves isolating the relevant cells from the patient, editing them in culture under carefully controlled conditions, and reinfusing them. This approach affords precise quality control over editing efficiency and off-target analysis before the product is returned to the patient, but it is logistically demanding, requires myeloablative conditioning regimens to clear the bone marrow prior to re-engraftment, and is restricted to cell types, principally HSPCs, T cells, and other easily harvested populations, that can survive manipulation outside the body.

In vivo delivery, which introduces CRISPR components directly into the organism and relies on them reaching the desired tissues, is far more versatile in principle but technically more demanding. Viral vectors, particularly AAV serotypes with defined tissue tropism, have been used extensively in research and some clinical applications but impose packaging capacity limits that exclude SpCas9 when combined with a promoter and guide RNA in a single construct. Lentiviral vectors can accommodate larger payloads but carry a non-trivial risk of insertional mutagenesis due to their semi-random genomic integration. Non-viral systems, led by lipid nanoparticles (LNPs), have emerged as the most promising platform for in vivo delivery and now dominate the clinical trial landscape for in vivo CRISPR approaches. LNPs encapsulate Cas9 mRNA and sgRNA together, delivering them transiently to target cells, most effectively to the liver following systemic administration. The transient nature of LNP-mediated delivery is considered advantageous for CRISPR specifically because the editing event is permanent while the nuclease is not, reducing the window for off-target cleavage in a “hit-and-run” fashion.

Emerging Non-Viral Platforms

Beyond LNPs, a range of engineered nanocarrier platforms including polymeric nanoparticles, metallic nanoparticles, and biologically derived vesicles such as exosomes are under active investigation. These platforms offer opportunities for tissue targeting beyond the liver through surface modification with targeting ligands. Some formulations are designed to be responsive to stimuli in the target microenvironment, such as pH-sensitive delivery that exploits the acidic conditions of tumour tissue, or magnetically guided particles for focal delivery. The ongoing challenge across all non-viral platforms is achieving therapeutic editing efficiency in tissues such as muscle, lung, brain, and the eye at acceptable doses and without unacceptable immunostimulation from the delivered nucleic acid components.

Off-Target Effects and the Safety Imperative

No dimension of CRISPR translational science is more consequential for patient safety than the accurate characterisation and minimisation of off-target editing. Cas9 tolerates a degree of mismatch between the sgRNA and genomic DNA, particularly at positions distal from the PAM, meaning that sites with sequences similar but not identical to the intended target can be cleaved at low frequency. The consequences of such aberrant cuts depend critically on their genomic location. An indel in a gene desert may be phenotypically silent, while the same event within a tumour suppressor gene could, in an oncogenic context, have severe consequences.

Comprehensive detection of off-target sites now relies on a portfolio of complementary methods. In silico tools predict potential off-target sites based on sequence homology. Biochemical assays performed on cell-free genomic DNA, such as GUIDE-seq, HTGTS, and CIRCLE-seq, identify sites of Cas9 activity in a largely unbiased manner. Cell-based assays including DISCOVER-Seq and CAST-Seq can detect off-target events in therapeutically relevant primary cells. However, as noted in recent literature, events that are detectable in cell-free assays may not occur at appreciable frequency in living cells, and the converse, where in vitro predictions underestimate in vivo activity, has also been observed, complicating the translation of safety data across experimental contexts.

High-fidelity Cas9 variants such as SpCas9-HF1 and eSpCas9 substantially reduce off-target cleavage by weakening non-specific DNA contacts. Base editors and prime editors, by avoiding DSBs, eliminate certain categories of gross chromosomal rearrangement, though they introduce their own specificity considerations: cytidine and adenine deaminase enzymes can act on single-stranded RNA as well as the ssDNA exposed at the editing window, generating transcriptome-wide RNA off-target edits that must be assessed independently. For germline editing, where any off-target change would be heritable by all cells of the resulting organism and transmitted to subsequent generations, the ethical and regulatory stakes are categorically higher, and current international consensus holds that heritable human germline editing should not proceed in clinical contexts until safety and ethical frameworks are substantially more mature.

CRISPR in Agriculture, Diagnostics, and Functional Genomics

Crop and Livestock Engineering

Medicine has understandably captured the largest share of public and scientific attention, but the applications of CRISPR in agriculture and food systems are equally consequential. In plant biology, CRISPR has been used to generate crops with improved resistance to drought, heat, and fungal pathogens, to modify nutritional composition, and to introduce traits that were technically impractical with conventional plant breeding on any reasonable timescale. A notable example is the development of disease-resistant wheat varieties through targeted disruption of mildew locus O genes, which had previously required decades of backcrossing. In livestock, pigs with disrupted endogenous retroviral sequences have been generated as a step toward safer xenotransplantation, and cattle with disrupted MSTN (myostatin) genes have been engineered for enhanced muscle development.

Regulatory frameworks for CRISPR-edited agricultural products vary significantly between jurisdictions. In the United States, the USDA has determined that certain CRISPR-edited plants that do not contain introduced genetic material fall outside the scope of existing biotechnology regulations, enabling them to reach the market more rapidly than transgenic crops. The European Union has historically applied a stricter regulatory framework, though ongoing policy revision processes reflect growing scientific evidence that CRISPR-derived changes are often indistinguishable from those arising naturally through mutation, and regulatory recalibration is anticipated.

Diagnostics: SHERLOCK and DETECTR

CRISPR has also found application in nucleic acid diagnostics. The collateral cleavage activity of Cas12 and Cas13 enzymes, in which target recognition activates indiscriminate single-stranded nuclease activity that cleaves nearby reporter molecules, has been harnessed in platforms including SHERLOCK (Specific High-Sensitivity Enzymatic Reporter UnLOCKing), which uses LwCas13a, and DETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter), based on AsCas12a. Both systems can detect specific nucleic acid sequences at attomolar to femtomolar concentrations in patient samples, with results readable by lateral flow strips or fluorescent readout within an hour. These platforms demonstrated clinical utility during the COVID-19 pandemic and are being developed for applications in infectious disease surveillance, oncology (liquid biopsy), and pathogen identification in resource-limited settings.

Functional Genomics at Scale

CRISPR pooled screens represent a third major application domain beyond therapy and diagnostics. Genome-wide loss-of-function screens using libraries of tens of thousands of sgRNAs, delivered at approximately one guide per cell, allow researchers to systematically perturb each gene in the genome and assess the effect on any measurable phenotype, whether growth, drug sensitivity, protein interaction, or cell state. CRISPRi (CRISPR interference), which uses a catalytically dead dCas9 fused to repressive chromatin domains such as KRAB, enables reversible transcriptional silencing without permanent sequence modification. CRISPRa (CRISPR activation) uses dCas9 fused to transcriptional activators to upregulate endogenous genes. Together, these tools have enabled the systematic mapping of genetic dependencies in cancer cell lines, the identification of new drug targets, and the functional annotation of non-coding regulatory elements across the genome.

Ethical Dimensions and Societal Implications

The power of CRISPR to edit heritable genetic information places it at the intersection of molecular biology and a set of profound ethical questions that have no clean technical resolution. The case of He Jiankui, who in 2018 announced the birth of gene-edited human embryos carrying disruptions in the CCR5 gene, ostensibly to confer resistance to HIV, was widely condemned by the scientific community and by ethicists as a premature and unjustifiable act that violated established norms of informed consent, regulatory oversight, and safety verification. He was subsequently convicted of illegal medical practice in China and sentenced to three years in prison. The episode catalysed an ongoing international conversation about the conditions, if any, under which heritable human germline editing could be ethically pursued.

The core ethical issues are interrelated and recurrent. Questions of consent are foundational: a future person whose genome was edited as an embryo cannot give informed consent to that modification, and any heritable off-target changes are similarly imposed on all descendants. The distinction between therapeutic editing to prevent severe monogenic disease and enhancement editing to augment traits in non-diseased individuals is conceptually important but technically difficult to police, and the line between the two is contested. Equity and access represent a distinct but equally serious concern. Casgevy is priced at approximately 2.2 million dollars per patient in the United States, raising acute questions about whether therapies that are technically curative will function as cures in practice for the populations that bear the highest burden of disease, particularly in sub-Saharan Africa, where sickle cell disease prevalence is highest. Reimbursement negotiations between CRISPR Therapeutics/Vertex and public payers including the UK National Health Service and US state Medicaid programmes are ongoing and have made some progress, but a durable model for equitable global access has not been established.

The Genome-Editing Toolbox Expands: Integrating AI and Next-Generation Architectures

The convergence of CRISPR technology with artificial intelligence has opened additional dimensions of capability. Machine learning models trained on large experimental datasets are now being used to predict sgRNA on-target activity and off-target cleavage propensity, to optimise pegRNA architecture for prime editing, and to design high-fidelity Cas9 variants through structure-guided mutagenesis. Tools such as GuideScan2 and DeepMEns (an ensemble model for predicting sgRNA on-target activity based on multiple features) represent the current state of computational guide RNA design as of 2025 and 2026. These models substantially reduce the experimental iteration required to identify optimal guide RNAs for new targets and to anticipate potential safety liabilities before entering cells.

Programmable transposases represent another category of next-generation architecture. Systems derived from the Tn7 transposon and its CRISPR-associated variants, including CAST (CRISPR-associated transposase) systems, can insert DNA cargo at defined genomic sites without creating a DSB and without requiring HDR, which is advantageous for large-scale gene insertion in post-mitotic cells and in cell types where HDR efficiency is low. The efficiency and specificity of these systems in human cells is still being characterised, but early results are sufficiently promising that multiple groups have prioritised their development for gene therapy applications. Similarly, epigenome editors that use dCas9 fused to DNA methyltransferases, demethylases, histone acetyltransferases, or deacetylases allow stable modulation of gene expression without altering the DNA sequence itself, adding a layer of regulatory precision that is particularly relevant for diseases driven by aberrant epigenetic states rather than coding sequence mutations.

A Technology at the Threshold of Its Potential

The story of CRISPR is, in one sense, already a story of extraordinary accomplishment. A decade elapsed between the first biochemical characterisation of Cas9 as a reprogrammable nuclease and the regulatory approval of a CRISPR-derived medicine, a timeline that is unprecedented for a technology of this complexity. The precision, versatility, and relative accessibility of the CRISPR toolkit have democratised genome editing research, enabling laboratories worldwide to ask and answer questions that were simply intractable a generation earlier.

Yet the most consequential chapters remain to be written. The 136 ongoing clinical trials as of late 2025 represent the early deployment of a platform that researchers expect to extend into immunology, neurology, and regenerative medicine. The in vivo delivery problem, which currently constrains systemic editing largely to the liver for LNP-based approaches, will determine the speed with which CRISPR can address diseases of muscle, lung, central nervous system, and other recalcitrant tissues. Base and prime editing will continue to improve in efficiency and reduce residual off-target risk, and the AI-guided design of editing components will compress development timelines. The ethical architecture governing where and how this technology is deployed, particularly with respect to germline editing and global access, must evolve with comparable urgency. The biology encoded in the human genome is in principle now editable. What that means for medicine, for agriculture, for our understanding of life, and for the societies that must govern these capabilities is a question that science answers only partially, and that the rest of human deliberation must address in full.

References

1. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., and Charpentier, E. “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity.” Science. 2012.
2. Doudna, J. A. and Charpentier, E. “The New Frontier of Genome Engineering with CRISPR-Cas9.” Science. 2014.
3. Moon, S. B., Kim, D. Y., Ko, J. H., and Kim, Y. S. “Recent Advances in the CRISPR Genome Editing Tool Set.” Experimental and Molecular Medicine. 2019.
4. Azeez, S. S., Hamad, R. S., Hamad, B. K., Shekha, M. S., and Bergsten, P. “Advances in CRISPR-Cas Technology and Its Applications: Revolutionising Precision Medicine.” Frontiers in Genome Editing. 2024.
5. U.S. Food and Drug Administration. “FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease.” U.S. Department of Health and Human Services. 2023.
6. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., and Liu, D. R. “Programmable Editing of a Target Base in Genomic DNA Without Double-Stranded DNA Cleavage.” Nature. 2016.
7. Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., and Liu, D. R. “Search-and-Replace Genome Editing Without Double-Strand Breaks or Donor DNA.” Nature. 2019.
8. Innovative Genomics Institute. “CRISPR Clinical Trials: A 2025 Update.” University of California, Berkeley. 2025.
9. Gwon, L. W., Badon, I. W., Lee, Y., Kim, H. J., and Lee, S. H. “Advances in Large-Scale DNA Engineering with the CRISPR System.” Experimental and Molecular Medicine. 2025.
10. Xu, W., Zhang, S., Qin, H., and Yao, K. “From Bench to Bedside: Cutting-Edge Applications of Base Editing and Prime Editing in Precision Medicine.” Journal of Translational Medicine. 2024.
11. Petrova, I. O. and Smirnikhina, S. A. “The Development, Optimization and Future of Prime Editing.” International Journal of Molecular Sciences. 2023.
12. National Institute of Health. “The CRISPR-Cas9 System: A Molecular Scalpel for Genome Editing.” National Human Genome Research Institute. 2023.
13. Tsuchida, C. A., Zhang, S., and Doost, M. S. “Expanding the Genome Editing Toolbox: CRISPR-Cas Variants, Base Editors, Prime Editors, and Beyond.” Journal of Biological Chemistry. 2024.
14. Schmidt, H., Zhang, M., Chakarov, D., Bansal, V., Mourelatos, H., and Sanchez-Rivera, F. J. “Genome-Wide CRISPR Guide RNA Design and Specificity Analysis with GuideScan2.” Genome Biology. 2025.
15. Riesenberg, S. et al. “Improved gRNA Secondary Structures Allow Editing of Target Sites Resistant to CRISPR-Cas9 Cleavage.” Nature Communications. 2022.
16. Advancing CRISPR Genome Editing into Gene Therapy Clinical Trials: Progress and Future Prospects. PMC Open Access. Oxford University Press. 2025.
17. Non-Viral CRISPR Carriers: Transient Delivery with Lasting Effects. National Center for Biotechnology Information. 2025.
18. Ding, S., Zheng, J., and Jia, C. “DeepMEns: An Ensemble Model for Predicting sgRNA On-Target Activity Based on Multiple Features.” Briefings in Functional Genomics. 2025.
19. World Health Organization. “Human Genome Editing: A Framework for Governance.” WHO Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. 2021.